CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Kyung-Hun Lee, Joohyuk Sohn, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Seock-Ah Im, Sung-Bae Kim

Cancer Research and Treatment. 2021;53(4):1084-1095. Published online 2021 March 24 DOI: https://doi.org/10.4143/crt.2020.1381

Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Kyung-Hun Lee, Joohyuk Sohn, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Seock-Ah Im, Sung-Bae Kim

Cancer Research and Treatment. 2021;53(4):1084-1095

Link1

Link2 Link3

Talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in Asian patients (Pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCA1/2mut): Data from phase III EMBRACA

K.-H. Lee, S.-B. Kim, J. Sohn, A. Goodwin, T. Usari, S. Lanzalone, Y.-H. Im

Annals of Oncology. 2019;30:ix14

Link1 Link2 Link3

Link4

269P Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial

H.S. Rugo, A. Niyazov, H. Bhattacharyya, B. Arondekar, S.A. Hurvitz

Annals of Oncology. 2021;32:S480

Link1 Link2

PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2− ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN’S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS

Anthony Gonçalves, Ruben G.W. Quek, Helen Bhattacharyya, Johannes Ettl, Sara A. Hurvitz, Hope S. Rugo

The Breast. 2019;48:S71

Link1 Link2

Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease

J. Ettl, R.G.W. Quek, H. Bhattacharyya, H.S. Rugo, S.A. Hurvitz, A. Gonçalves

Annals of Oncology. 2019;30:v129-v130

Link1 Link2 Link3

Patient-reported outcomes (PROs) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA HR+/HER2- subpopulation

Sara A. Hurvitz, Ruben G.W. Quek, Johannes Ettl, Hope Rugo, Helen Bhattacharyya, Alison L. Hannah, Jennifer Keating Litton

The Breast. 2018;41:S27-S28

Link1 Link2

Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation

H.S. Rugo, R. Quek, J. Ettl, S.A. Hurvitz, H. Bhattacharyya, A.L. Hannah, J.K. Litton

Annals of Oncology. 2018;29:viii91

Link1 Link2 Link3

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Y. Yu, M. Elmeliegy, J.K. Litton, I.C. Tudor, A. Czibere, J. Zheng, D.D. Wang

Annals of Oncology. 2018;29:viii97

Link1 Link2 Link3

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

J.K. Litton, S.A. Hurvitz, L.A. Mina, H.S. Rugo, K.-H. Lee, A. Gonçalves, S. Diab, N. Woodward, A. Goodwin, R. Yerushalmi, H. Roché, Y.-H. Im, W. Eiermann, R.G.W. Quek, T. Usari, S. Lanzalone, A. Czibere, J.L. Blum, M. Martin, J. Ettl

Annals of Oncology. 2020;31(11):1526-1535

Link1 Link2

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

J. Ettl, R.G.W. Quek, K.-H. Lee, H.S. Rugo, S. Hurvitz, A. Gonçalves, L. Fehrenbacher, R. Yerushalmi, L.A. Mina, M. Martin, H. Roché, Y.-H. Im, D. Markova, H. Bhattacharyya, A.L. Hannah, W. Eiermann, J.L. Blum, J.K. Litton

Annals of Oncology. 2018;29(9):1939-1947

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.